Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alliance for Clinical Trials in Oncology
With
National Cancer Institute (NCI)
OBJECTIVES:
* Determine the frequency of cytopenic response in patients with T-cell large granular lymphocytic leukemia treated with cyclosporine.
OUTLINE: This is a multicenter study.
Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 4 months for 1 year and then every 6 months for 9 years.
PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 3 years.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosis of T-cell large granular lymphocytic leukemia
* Increased numbers of large granular lymphocytes in peripheral blood smears
* CD3+CD8+CD57+ immunophenotype by flow cytometry AND
* CD3+CD57+ cell count at least 2,000/mm\^3 OR
* CD3+CD57+ cell count at least 500/mm\^3 with clonal T-cell receptor beta gene rearrangement
Patients must have at least 1 of the following:
* Severe neutropenia (absolute neutrophil count (ANC) less than 500/mm\^3)
* Neutropenia (ANC less than 1,000/mm\^3) and recurrent infections
* Anemia (hemoglobin less than 9 g/dL)
* Thrombocytopenia (platelet count less than 50,000/mm\^3)
PATIENT CHARACTERISTICS:
Age:
18 and over
Performance status:
NCI CTC 0-3
Hematopoietic:
See Disease Characteristics
Hepatic:
Bilirubin no greater than 2 times upper limit of normal (ULN)
Renal:
Creatinine no greater than 2 times ULN
Other:
Not pregnant or nursing
Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Endocrine therapy:
No concurrent hormonal therapy except steroids for adrenal failure or hormones for nondisease-related conditions (e.g., insulin for diabetes)
No concurrent dexamethasone or other steroidal antiemetics
Other:
No prior cyclosporine therapy for this leukemia
Clareo Health | Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
